SenoVax™ First-in-Class Senolytic Product to be Presented at Society for Immunotherapy of Cancer Symposium
MIAMI, March 5, 2025 /PRNewswire/ -- Immorta Bio Inc., a leader in longevity-focused biotechnologies, announced today acceptance of its poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) Spring Scientific, Cellular Therapy for Solid Tumors in San Diego, CA, on March 12-13, 2025.
The company will present molecular and cellular mechanisms by which its First-In-Class Senolytic Immunotherapy specifically kills senescent cells associated with cancer initiation, progression, and protection.
"We plan to present data demonstrating regression of cancers in animal models of glioma, lung, breast, and pancreatic cancers using our SenoVax approach," said Dr. Thomas Ichim, President and Chief Scientific Officer of Immorta Bio. "SenoVax is an autologous senescent cell pulsed dendritic cell product for which we plan to start clinical trials for lung cancer shortly.
The poster is a result of Immorta Bio collaboration with esteemed institutions, including the University of California San Diego, George Washington University, Cedars-Sinai, and Calidi Biosciences.
"The Society for Immunotherapy of Cancer is the world's leading organization dedicated to the advancement of cancer immunotherapy. For us to be selected to present in front of such a distinguished audience is significant accomplishment and indicates acceptance of our "paradigm-shifting" approach in that we kill cancer by targeting the senescent cells surrounding it," said Dr. Boris Reznik, Chairman and CEO of Immorta Bio. "Based upon our preclinical data we anticipate to also see SenoVax™ to reduce systemic senescent cells load resulting in associated "antiaging" effects in treated patients."
About Immorta Bio
Immorta Bio Inc., a scientific longevity company focused on "Treating Diseases of Aging and Treating Aging as Disease™," leverages anti-aging technologies to tackle pressing medical challenges, from advanced cancers to other age-related conditions. To learn more about Immorta Bio' research initiatives, visit immortabio.com, LinkedIn and X.
Company Contact
Dr. Boris Reznik
Immorta Bio
https://www.immortabio.com
+1 305-632-2939
